Anti il 9 percp cy5

Manufactured by BD

Anti-IL-9 PerCP-Cy5.5 is a fluorescently-labeled antibody that binds to the interleukin-9 (IL-9) cytokine. This reagent can be used for the detection and quantification of IL-9-expressing cells in flow cytometry applications.

Automatically generated - may contain errors

Lab products found in correlation

Anti cd4 apc cy7, by BD (2 mentions) Anti il 2 bv711, by BD (2 mentions) Anti il 17f bv786, by BD (2 mentions) Anti tnf α buv395, by BD (2 mentions) Anti il 13 bv421, by BD (2 mentions) Anti il 17a apccy7, by BioLegend (2 mentions) Anti cd25 pe cy7, by BD (2 mentions) Recombinant human il 12, by R&D Systems (1 mentions) Efluor660 anti il 21, by Thermo Fisher Scientific (1 mentions) Anti cd45ra fitc, by Thermo Fisher Scientific (1 mentions) Sa percpcy5, by BD (1 mentions) Anti icos pe, by Thermo Fisher Scientific (1 mentions) Anti il4 pe cy7, by BioLegend (1 mentions) Anti cd45ra percp cy5, by Thermo Fisher Scientific (1 mentions) Anti cd34 fitc, by BD (1 mentions) Anti ccr7 fitc, by R&D Systems (1 mentions) Apc anti cd10, by BD (1 mentions) Anti cd27 pe cy7, by BD (1 mentions) Anti cd27 pe, by BD (1 mentions) Anti cd45ra bv 605, by BD (1 mentions)

2 protocols using anti il 9 percp cy5

Comprehensive Immunophenotyping Panel

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following were purchased from eBiosciences: anti-IL-21 eFluor660, anti-IL-10 Alexa Fluor 488, anti-IFNγ BV605, anti-CD45RA FITC, anti-ICOS PE, anti-PD-1 biotin. The following were purchased from Becton Dickinson: anti-CXCR5 Alexa Fluor 647, anti-CD4 APC-Cy7, anti-IL-2 BV711, anti-CD25 PE-Cy7, anti-CD127 PerCP-Cy5.5, SA-PerCpCy5.5, anti-IL-17F BV786, anti-TNFα BUV395, anti-IL-9 PerCP-Cy5.5, anti-IL-13 BV421. The following were purchased from Biolegend: anti-IL-22 PE, anti-IL-4 PE-Cy7, anti-IL-17A APC-Cy7. The TCR Vß repertoire kit was from Beckman Coulter. Recombinant human IL-12 was purchased from R&D Systems.

Bier J., Rao G., Payne K., Brigden H., French E., Pelham S.J., Lau A., Lenthall H., Edwards E.S., Smart J.M., Cole T.S., Choo S., Joshi A.Y., Abraham R.S., O’Sullivan M., Boztug K., Meyts I., Gray P.E., Berglund L.J., Hsu P., Wong M., Holland S.M., Notarangelo L.D., Uzel G., Ma C.S., Brink R., Tangye S.G, & Deenick E.K. (2019). Activating mutations in PIK3CD and murine CD4+ T cells. The Journal of allergy and clinical immunology, 144(1), 236-253.

+ Open protocol

+ Expand

Comprehensive Immune Cell Profiling

Check if the same lab product or an alternative is used in the 5 most similar protocols

The following mAbs were used: anti-CD20 BUV395, anti-CD10 APC, anti-CD4 BUV737, anti-CD4 APCCy7, anti-CD25 PECy7, anti-CD27 PECy7, anti-CD27 PE, anti-CD45RA BV605, anti-CXCR5 A647, anti-IgG APC, anti-IgG PE, anti-IgG BV605, anti-CD8 BUV395, anti-PD1 BV605, Streptavidin-PerCPCy5.5, anti-IgM PerCPCy5.5, anti-CD3 BV421, anti-IL-2 BV711, anti-IL-9 PerCPCy5.5, anti-IL-13 BV421, anti-IL-17F BV786, anti-IFN-γ BV605, anti-TNF-α BUV395, anti-CD19 BV711, anti-CD34 FITC, anti-CCR6 PE (all from Becton Dickinson); anti-CCR7 PECy7, anti-CD127 BV650, anti-IL-17A APCCy7, anti-CD20 Pacific Blue, anti-FoxP3 PE, anti-CXCR3 BV421 (BioLegend); anti-CD45RA PerCPCy5.5 (eBioscience); anti-CCR7 FITC (R&D Systems); anti-IgA-biotin (SouthernBiotech); anti-IL-4 PECy7, anti-IL-21 e660, anti-IL-22 PE (Thermo Fisher Scientific).

Nguyen T., Lau A., Bier J., Cooke K.C., Lenthall H., Ruiz-Diaz S., Avery D.T., Brigden H., Zahra D., Sewell W.A., Droney L., Okada S., Asano T., Abolhassani H., Chavoshzadeh Z., Abraham R.S., Rajapakse N., Klee E.W., Church J.A., Williams A., Wong M., Burkhart C., Uzel G., Croucher D.R., James D.E., Ma C.S., Brink R., Tangye S.G, & Deenick E.K. (2023). Human PIK3R1 mutations disrupt lymphocyte differentiation to cause activated PI3Kδ syndrome 2. The Journal of Experimental Medicine, 220(6), e20221020.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!